Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ERYPO
recombinant human erythropoietin alfa · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| placebo | PLACEBO_COMPARATOR | 50ml 0.9% NaCL |
| verum | ACTIVE_COMPARATOR | erythropoietin alfa 40,000 IU iv in 50ml 0.9% NaCl |
| Name | Type | Description |
|---|---|---|
| recombinant human erythropoietin alfa | DRUG | 40,000 IU in 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms |
| 0.9% NaCl | DRUG | 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms |
Inclusion Criteria: * Ischemic stroke in the middle cerebral artery territory * Clearly defined time of onset * Confirmed by MRI (DWI, Flair) * NIH Stroke Scale ≥ 5 * Age \> 18 years * Treatment within 6h after onset of symptoms * Informed consent by patient, relatives or independent physician * Li...
Recombinant human erythropoietin alfa is an investigational exogenous protein being studied by Johnson & Johnson for acute ischemic stroke, specifically infarction of the middle cerebral artery. It has been tested in a single completed Phase 2 clinical trial in Germany. It is not described as approved for this indication.
It is being studied as a treatment for acute ischemic stroke caused by middle cerebral artery infarction. The research focuses on patients 18 years and older with acute stroke. The only recorded trial, NCT00604630, has completed, and no active trials are currently listed.
Recombinant human erythropoietin alfa is an exogenous protein directed at the F9 target. Its target class is classified as an exogenous protein, meaning the drug itself is a protein-based agent rather than a conventional small molecule therapeutic.
Johnson & Johnson, which trades under the ticker JNJ, is the developer of recombinant human erythropoietin alfa. The company sponsored the Phase 2 study of the drug in acute ischemic stroke.
Recombinant human erythropoietin alfa is in Phase 2 development. One Phase 2 trial has been completed, and no trials are currently active. It is an investigational therapy and is not described as FDA approved for middle cerebral artery infarction.
Recombinant human erythropoietin alfa has been studied in NCT00604630, a multicenter Phase 2 efficacy study in acute ischemic stroke. The trial was completed in Germany, enrolled 522 patients, and used a randomized, double-blind, placebo-controlled design with participants aged 18 years and older.